Last reviewed · How we verify
hypoxia-activated prodrug TH-302
At a glance
| Generic name | hypoxia-activated prodrug TH-302 |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Mucositis oral
- Neutrophil count decreased
- Diarrhea
- Anorexia
- Dysgeusia
- Hypertension
- Nausea
- Platelet count decreased
- Palmar-plantar erythrodysesthesia syndrome
- Vomiting
- Headache
Key clinical trials
- Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer (PHASE2)
- Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma (PHASE1, PHASE2)
- Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma (PHASE2)
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer (PHASE1)
- A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma (PHASE2)
- Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (PHASE3)
- A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours (PHASE2)
- TH-302 in Combination With Bevacizumab for Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: